GoldenGolden
Advanced Search
Aprinoia Therapeutics

Aprinoia Therapeutics

Aprinoia Therapeutics is a developer of diagnostics, therapeutics and drug discovery platform for neurological diseases.

Aprinoia Therapeutics is a company that discovers and develops diagnostics and therapeutics for Alzheimer’s Disease and other tau-associated neurodegenerative diseases (Tauopathies). It achieves its mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with scientists, research institutions and pharmaceutical companies, to bring innovative ideas and scientific discoveries to life.

The company is committed to establishing a drug discovery and early-stage development company that is based on innovation, scientific rigor and integrity. Its goal is to develop novel products to address significant patients' needs, including: Novel imaging-based diagnostic tools to enhance the detection of occurrence, progression, and regression of neurological diseases; and Novel therapies to enhance the treatment of human neurological conditions.

Timeline

January 2018
Aprinoia Therapeutics raises a $11,100,000 series B round from DCI Partners, KTB Network, ShangPharma and TaiAn Technologies.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Insilico Medicine Hong Kong Limited
December 30, 2020
www.prnewswire.com:443
/PRNewswire/ -- Insilico Medicine is pleased to announce that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico's...
APRINOIA Therapeutics
December 16, 2020
www.prnewswire.com:443
/PRNewswire/ -- APRINOIA Therapeutics Inc. today announced that they had executed a worldwide non-exclusive licensing agreement for Biogen Inc. (Nasdaq: BIIB)...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.